This patent teaches was of targeting damaged tissue with genes that stimulate angiogenesis. Conceptually the technology could be modified to introduce agents which actually stimulate stem cell proliferation at the site of injury. The patent has one issued claim that covers a fusion polypeptide, with one end having a collagen binding domain which binds exposed vascular collagen (ie during tissue injury collagen become exposed) and an angiogenesis modulating domain which triggers the proliferation of endothelial cells. Variants of this technology are currently used clinically by the company EPEIUS BIOTECHNOLOGIES.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.